Skip to main content
. 2019 Jul 2;33(12):1819–1830. doi: 10.1097/QAD.0000000000002288

Fig. 1.

IL-27 exhibits anti-HIV effects in primary CD4+ T cells.

Fig. 1

(a) IL-27 pretreatment inhibits HIV-1 replication in CD4+ T cells. Untreated (control) or IL-27-treated (treated) CD4+ T cells were infected with replication-competent HIV-1 and cultured for 7 days. A p24 ELISA was performed on the seventh day postinfection to quantitate the HIV p24 antigen in supernatants of HIV-infected control and treated cells. Relative HIV replication was compared between control and treated cells. Data show mean ± standard errors from three independent assays. (b) IL-27 pretreatment inhibits pseudo-typed HIV-1 (HIV-LUC-G) infection. Control and treated cells were infected with HIV-Luc-G virus and then cultured for 2 days. HIV infection was monitored by luciferase activity in cells. Relative HIV infection was compared between control and treated cells. Data show mean ± standard errors from seven independent assays.